Abbvie Inc (ABBV)

$243.14 +8.25 (3.51%)
Market Cap 415.00B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.04
Forward PE 16.42
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 10,281,800
Avg Vol 6,293,958
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 95%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 4:08 AM
$SLS $ABBV $GLSI
0 · Reply
Ragnar_Lothbrokk
Ragnar_Lothbrokk Jun. 26 at 3:32 AM
$ABBV $GLSI $SLS This dudes a clown. Ignore.
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 9:21 PM
$SLS https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results $ABBV Modified the VIALE-M Phase 3 SAP 7 times. - you can see. 7 times TRYING to find a regime that worked, and was not Toxic, Varying Reduced Aza / Varying Reduced VEN All ORAL, IV and Subq --- all Failed --- BAT is Toxic. Meanwhile REGAL Phase 3 Trial Clinicians Requested Expanded Access and Extended Dosing ---- Buy and Hold as many as You can. - it is not complicated $GLSI
0 · Reply
Game_Day
Game_Day Jun. 25 at 8:26 PM
June 25 Thank gd much better today Highlights / alerts $ABT $ABBV $BNC $CRM
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 25 at 7:57 PM
$0.72 on $ABBV here! 🩺 67% return! 🔥
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 25 at 7:54 PM
$0.72 on $ABBV here! 67% return
0 · Reply
biolover
biolover Jun. 25 at 7:24 PM
$VKTX Been watching $ABBV meteoric rise post apge deal. Listening to CMO shows some confusion re obesity mechanisms etc. rumor ABBV was looking for same molecule as $NVO …. Abbv could make market rerating of large pharma valuations with a serious obesity M&A and pose serious competition to $LLY But my sense they don’t command good understanding of the field to do that.
1 · Reply
genomanetti
genomanetti Jun. 25 at 6:55 PM
$ABBV baked in revenue plus new medicine initiatives and strong cash flow plus sustain predictable dividends.
0 · Reply
Noxcapitaltrade
Noxcapitaltrade Jun. 25 at 6:43 PM
$ABBV $0.63 on $ABBV here! 🩺 46% return! 🔥
0 · Reply
Latest News on ABBV
AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 1 day ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 1 day ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:54:44.000Z - 2 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

2026-06-23T12:22:00.000Z - 2 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 2 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 2 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 2 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 2 days ago

AbbVie announces European Commission approval for Skyrizi

AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 2 days ago

AbbVie announces European Commission approval of Maviret

AbbVie announces EU approval of Skyrizi for pediatric patients

2026-06-23T09:46:03.000Z - 2 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 2 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 2 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

2026-06-22T21:55:09.000Z - 3 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 3 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 3 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 3 days ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 3 days ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 3 days ago

AbbVie Press release: M&A announcement

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

2026-06-22T12:24:03.000Z - 3 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 3 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 3 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

2026-06-22T11:10:51.000Z - 3 days ago

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 3 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 3 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 3 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

2026-06-22T10:48:07.000Z - 3 days ago

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

APGE CLDX CNTB EVMN KYMR NKTR

BTIG says others may be interested in Apogee Therapeutics

2026-06-22T10:40:59.000Z - 3 days ago

BTIG says others may be interested in Apogee Therapeutics

APGE CBIO JBIO JNJ NVS ORKA PFE

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

2026-06-22T10:23:29.000Z - 3 days ago

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

APGE REGN

AbbVie near deal to acquire Apogee Therapeutics, FT reports

2026-06-22T09:00:15.000Z - 3 days ago

AbbVie near deal to acquire Apogee Therapeutics, FT reports

APGE

‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition

2026-06-22T05:55:55.000Z - 4 days ago

‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition

APGE REGN SNY

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 5 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 6 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 7 days ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 9 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 13 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 14 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 15 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 16 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 17 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 22 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 22 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 23 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 27 days ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 4 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 5 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 5 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 6 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 7 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 7 weeks ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 7 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 2 months ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 2 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 2 months ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 2 months ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 2 months ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 4:08 AM
$SLS $ABBV $GLSI
0 · Reply
Ragnar_Lothbrokk
Ragnar_Lothbrokk Jun. 26 at 3:32 AM
$ABBV $GLSI $SLS This dudes a clown. Ignore.
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 9:21 PM
$SLS https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results $ABBV Modified the VIALE-M Phase 3 SAP 7 times. - you can see. 7 times TRYING to find a regime that worked, and was not Toxic, Varying Reduced Aza / Varying Reduced VEN All ORAL, IV and Subq --- all Failed --- BAT is Toxic. Meanwhile REGAL Phase 3 Trial Clinicians Requested Expanded Access and Extended Dosing ---- Buy and Hold as many as You can. - it is not complicated $GLSI
0 · Reply
Game_Day
Game_Day Jun. 25 at 8:26 PM
June 25 Thank gd much better today Highlights / alerts $ABT $ABBV $BNC $CRM
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 25 at 7:57 PM
$0.72 on $ABBV here! 🩺 67% return! 🔥
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 25 at 7:54 PM
$0.72 on $ABBV here! 67% return
0 · Reply
biolover
biolover Jun. 25 at 7:24 PM
$VKTX Been watching $ABBV meteoric rise post apge deal. Listening to CMO shows some confusion re obesity mechanisms etc. rumor ABBV was looking for same molecule as $NVO …. Abbv could make market rerating of large pharma valuations with a serious obesity M&A and pose serious competition to $LLY But my sense they don’t command good understanding of the field to do that.
1 · Reply
genomanetti
genomanetti Jun. 25 at 6:55 PM
$ABBV baked in revenue plus new medicine initiatives and strong cash flow plus sustain predictable dividends.
0 · Reply
Noxcapitaltrade
Noxcapitaltrade Jun. 25 at 6:43 PM
$ABBV $0.63 on $ABBV here! 🩺 46% return! 🔥
0 · Reply
LUXtrades0
LUXtrades0 Jun. 25 at 6:40 PM
$ABBV 245 CALL 6/26 @ 1.80
0 · Reply
leifstocks
leifstocks Jun. 25 at 6:39 PM
$ABBV 245 CALL 6/26 @ 1.80
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 25 at 6:38 PM
$ABBV 245 CALL 6/26 @ 1.80
0 · Reply
Blockwave1
Blockwave1 Jun. 25 at 6:32 PM
$0.60 on $ABBV here! 🌊40% return! 🔥
0 · Reply
Noxcapitaltrade
Noxcapitaltrade Jun. 25 at 6:31 PM
$ABBV $0.60 on $ABBV here! 🩺 40% return! 🔥
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 6:20 PM
$SLS IDMC ALREADY UNBLINDED ACTUAL PHASE 3 MOS AND IR DATA from the INTERIM ANALYSIS at 60 EVENTS... - SMARTER MONEY THAN US KNOWS GPS IS THE REASON WE CONTINUE TO WAIT FOR NEAR MIRACULOUS EXTENDED SURVIVAL DATA. BAT $ABBV FAILED - 4 RECENT TRIALS - 3 for AML REMISSION MAINTENANCE.
1 · Reply
LiveTradePro
LiveTradePro Jun. 25 at 5:40 PM
$ABBV Beautiful breakout https://share.trendspider.com/chart/ABBV/6682tsexcw
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 5:10 PM
$SLS https://www.reddit.com/r/sellasLifescience/ Anyone interested in Money should be attempting to Quantify GPS Value --- What is GPS Worth? https://www.reddit.com/r/sellasLifescience/ $28B Total Addressable Market Imminently due Phase 3 Results will give Gps the FDA Green Light to Generate 10's of Billions in Real Dollars --- Do not Be Surprised if we see $ABBV PR trying to Buy SLS CHeap for $30B. --- will be Massive Class Action for Selling too Cheap
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 4:54 PM
$SLS $ABVX $ABBV pardon me for the error: Aza+VEN Failed 2 Phase 3 AML Remission Maintenance trials, and just weeks ago - a Phase 2 - low intensity, all oral P2 Aza Ven Trial Failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 4:29 PM
$SLS $ABVX and for the short boys in the back... $ABBV Knows BAT Doesn't work and that its GPS doing what its done in all Prior trials.... Aza+VEN / BAT for Control ARM patients in the SLS REGAL Trial, Recently FAILED 3 Large Phase 3 Trials - Including 2 for AML Remission Maintenance. VIALE-M Phase 3 for First Remission CR1 Maintenance FAILED VIALE-T Phase 3 For Post Transplant Maintenance FAILED VERONA - High Risk MDS/AML Precursor FAILED Phase 2 Aza+VEN all oral, Low dose - FAILED - results at Ash.... ITS GPS DOING WHAT ITS DONE IN ALL 7 Trials including 2 for AML REMISSION MAINTENANCE.
0 · Reply
liamsniperalert
liamsniperalert Jun. 25 at 4:24 PM
0.57 on $ABBV here! 32% return! 🏆🗻
0 · Reply
PanicSeller8
PanicSeller8 Jun. 25 at 3:17 PM
$ABBV Quite the run!
0 · Reply